Market Overview:
The global Glucose Responsive Insulin System market is expected to grow at a CAGR of XX% and reach a value of USD XX million by 2030. The market is segmented on the basis of type, application and region. On the basis of type, the market is segmented into rapid acting, short acting, intermediate acting, long acting and premixed type. On the basis of application, the market is segmented into type 1 diabetes and type 2 diabetes. The North American region dominates the global Glucose Responsive Insulin System market followed by Europe and Asia Pacific regions respectively.
Product Definition:
The Glucose Responsive Insulin System (GRIS) is a closed-loop control system for regulating blood glucose levels in diabetic patients. The GRIS monitors blood sugar levels and automatically adjusts insulin doses accordingly, providing more accurate regulation than manual methods. The GRIS is an important tool for managing diabetes, as it can help to prevent dangerous spikes and drops in blood sugar levels.
Rapid Acting:
Rapid acting insulin is a type of short-acting insulin that works faster than long acting. The two types of rapid-acting insulins currently available in the market are premixed and regular premixed. They were approved by the U.S Food and Drug Administration (FDA) for use in diabetic patients who require an injection once or twice daily and have to manage with multiple daily injections, but have not been approved for use as monotherapy (for treating diabetes).
Short Acting:
Short acting insulin is also known as rapid-acting insulin. It is a type of short-acting human insulins, which has an active life shorter than 12 hours and has an effect on the glucose level in the body after consumption. Short acting type of insulin can be administered to patients who need to take their dose at a specific time or before certain events like meals.
Application Insights:
On the basis of application, the global market has been segmented into type 1 and type 2 diabetes. In 2017, type 1 diabetes dominated the market with a share of 69.1%. This is attributed to a high prevalence of this disease coupled with increasing usage of insulin for treating it. As per WHO, there are approximately 382 million people suffering from diabetes globally; out of which around 250 million suffer from Type 1 Diabetes (2017).
The introduction of new drugs and devices such as artificial pancreas that can automate some portion or all aspects of glucose management is expected to drive the growth over next seven years.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of manufacturers and an increasing prevalence of diabetes. The region is expected to maintain its dominance over the forecast period due to factors such as technological advancements, rising awareness about GRS, and availability of effective treatment in this region. Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to factors such as improving healthcare infrastructure & coverage, economic development, increase in disposable income & consumerism along with high unmet medical needs pertaining health issues associated with diabetes are some major drivers for regional growth. Moreover gluco- responsive insulin systems have been approved by regulatory agencies for sale across Asian countries which will further boost revenue generation from this region.
Major players operating in North America include Novo Nordisk; Sanofi; Eli Lilly and Company; J&J Diabetes Care Inc.
Growth Factors:
- Increasing prevalence of diabetes mellitus: The global prevalence of diabetes is increasing at an alarming rate. According to the World Health Organization (WHO), the number of people with diabetes has quadrupled since 1980 and as of 2014, there were 422 million people living with diabetes. This number is expected to reach 642 million by 2040. This growing population will create a large demand for glucose responsive insulin systems, driving market growth.
- Rising awareness about glycemic control: There is a growing awareness among patients and healthcare professionals about the importance of glycemic control in preventing long-term complications associated with diabetes mellitus such as heart disease, stroke, kidney failure, and blindness. As a result, there is an increasing demand for glucose responsive insulin systems that can help achieve better glycemic control in patients with type 1 or type 2 diabetes mellitus.
- Technological advancements: The development of novel glucose responsive insulin systems that are more accurate and easier to use is likely to drive market growth over the next few years. For example, Abbott’s FreeStyle Libre Flash Glucose Monitoring System does not require any finger prick blood tests for calibration or monitoring; instead it uses a small sensor worn on the back of patient’s upper arm which reads blood sugar levels every minute and sends data wirelessly to a handheld reader device which displays results onscreen in real time.. Such technological advancements are likely to increase adoption rates among patients and healthcare professionals alike,.
Scope Of The Report
Report Attributes
Report Details
Report Title
Glucose Responsive Insulin System Market Research Report
By Type
Rapid Acting, Short Acting, Intermediate Acting, Long Acting, Premixed Type
By Application
Type 1 Diabetes, Type 2 Diabetes
By Companies
CeQur Simplicity, Diamesco, Eli lily and Company, Insulet, Medtronic Diabetes, Novo Nordisk, Sanofi, Zealand Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
143
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Glucose Responsive Insulin System Market Report Segments:
The global Glucose Responsive Insulin System market is segmented on the basis of:
Types
Rapid Acting, Short Acting, Intermediate Acting, Long Acting, Premixed Type
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Type 1 Diabetes, Type 2 Diabetes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CeQur Simplicity
- Diamesco
- Eli lily and Company
- Insulet
- Medtronic Diabetes
- Novo Nordisk
- Sanofi
- Zealand Pharma
Highlights of The Glucose Responsive Insulin System Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Rapid Acting
- Short Acting
- Intermediate Acting
- Long Acting
- Premixed Type
- By Application:
- Type 1 Diabetes
- Type 2 Diabetes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glucose Responsive Insulin System Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The Glucose Responsive Insulin System (GRS) is a group of cells and proteins that help the body regulate blood sugar levels. When blood sugar levels are high, the GRS helps to release insulin to lower them. When blood sugar levels are low, the GRS helps to release glucagon to raise them.
Some of the major companies in the glucose responsive insulin system market are CeQur Simplicity, Diamesco, Eli lily and Company, Insulet, Medtronic Diabetes, Novo Nordisk, Sanofi, Zealand Pharma.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glucose Responsive Insulin System Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Glucose Responsive Insulin System Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Glucose Responsive Insulin System Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Glucose Responsive Insulin System Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Glucose Responsive Insulin System Market Size & Forecast, 2020-2028
4.5.1 Glucose Responsive Insulin System Market Size and Y-o-Y Growth
4.5.2 Glucose Responsive Insulin System Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Rapid Acting
5.2.2 Short Acting
5.2.3 Intermediate Acting
5.2.4 Long Acting
5.2.5 Premixed Type
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Type 1 Diabetes
6.2.2 Type 2 Diabetes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glucose Responsive Insulin System Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glucose Responsive Insulin System Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Rapid Acting
9.6.2 Short Acting
9.6.3 Intermediate Acting
9.6.4 Long Acting
9.6.5 Premixed Type
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Type 1 Diabetes
9.10.2 Type 2 Diabetes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Rapid Acting
10.6.2 Short Acting
10.6.3 Intermediate Acting
10.6.4 Long Acting
10.6.5 Premixed Type
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Type 1 Diabetes
10.10.2 Type 2 Diabetes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Rapid Acting
11.6.2 Short Acting
11.6.3 Intermediate Acting
11.6.4 Long Acting
11.6.5 Premixed Type
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Type 1 Diabetes
11.10.2 Type 2 Diabetes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Rapid Acting
12.6.2 Short Acting
12.6.3 Intermediate Acting
12.6.4 Long Acting
12.6.5 Premixed Type
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Type 1 Diabetes
12.10.2 Type 2 Diabetes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Rapid Acting
13.6.2 Short Acting
13.6.3 Intermediate Acting
13.6.4 Long Acting
13.6.5 Premixed Type
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Type 1 Diabetes
13.10.2 Type 2 Diabetes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glucose Responsive Insulin System Market: Competitive Dashboard
14.2 Global Glucose Responsive Insulin System Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CeQur Simplicity
14.3.2 Diamesco
14.3.3 Eli lily and Company
14.3.4 Insulet
14.3.5 Medtronic Diabetes
14.3.6 Novo Nordisk
14.3.7 Sanofi
14.3.8 Zealand Pharma
